We are a development-stage biotechnology company focused on advancing and commercializing our proprietary immunostimulatory platform technology derived from a plant virus, cowpea mosaic virus. Our lead immune-oncology candidate was carefully selected through preclinical testing. Data from numerous mouse tumor models and in companion dogs with naturally occurring tumors show the ability of intratumoral (“IT”) administration of CPMV to result in anti-tumor effects in treated tumors and systemically at other sites of disease through immune activation.
The development of our technology has been supported through numerous federal research grants, including NIH, NSF, and CDMRP as well as private foundations, such as the American Cancer Society, Susan G. Komen, and American Heart Association totaling over $20 Million. The research funding is ongoing and continues to advance the technology toward clinical development.
We are currently focused on advancing our lead immuno-oncology candidates, MIE-101 into human clinical trials and MIE-201 into canine studies. The canine studies offer the opportunity to inform and de-risk human trials, while also providing a potential expedited path toward the commercialization of our technology. In addition to research grants providing funds to advance our modular vaccine candidates, we are currently seeking strategic partners interested in furthering the program.